Cigna Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

The Cigna Group (CI)

AI-generated analysis

🏒 The Cigna Group is a diversified health services company with major operations in pharmacy benefit management, specialty pharmacy, and health insurance.

πŸ“ˆ Analyst sentiment remains strongly positive, with 87% of analysts currently rating Cigna as a Buy.

πŸ’° Insiders were net sellers of approximately $4.2M in Cigna stock over the last 90 days.

πŸ“‰ Technical signals are weakening in the near term, with MACD momentum declining and RSI remaining neutral.

🀝 Key clients include the US Department of Defense and health insurers like Centene.

πŸ’Š Specialty pharmacy is a critical component of Cigna's model due to the growing share of drug spending from complex medicines.

πŸ“œ The company operates primarily in the United States with international medical members as well.

πŸ›‘οΈ Cigna provides self-funded employer coverage where the company administers plans while employers bear cost risk.

πŸ“Š Market cap, P/E ratio, and other financial metrics are defined to help investors evaluate the company's valuation.

Bullish Signals
  • Analyst sentiment is strongly positive with 87% of analysts rating Cigna as a Buy.
  • No rating changes were recorded over the last 30 days, indicating stability in analyst consensus.
Risk Factors
  • Insiders were net sellers of approximately $4.2M in Cigna stock over the last 90 days.
  • Technical signals are weakening in the near term with MACD momentum showing a decline.
Full Analysis
The article provides a comprehensive overview of The Cigna Group (CI), describing it as a diversified health services company with significant operations in pharmacy benefit management, specialty pharmacy, health insurance, and employer benefits. Its business model focuses on helping employers, government clients, and individuals manage healthcare access, costs, and pharmacy spending, a strategy solidified by its 2018 combination with Express Scripts. Cigna's core PBM operations involve negotiating drug pricing, managing formularies, processing claims, and providing mail-order services to major institutional clients like the US Department of Defense and health insurers such as Centene. The company also offers medical insurance primarily through employer-sponsored self-funded arrangements where Cigna administers plans while employers bear cost risk. Financial and technical data indicates that analyst sentiment remains strongly positive, with 87% of analysts rating Cigna a Buy. However, insider selling has been the primary negative factor recently, with net sales of approximately $4.2M over the last 90 days. Technical signals are mixed, showing weakening MACD momentum and neutral RSI, suggesting no clear long-term trend in the near term. The text concludes by defining various financial metrics such as market cap, P/E ratio, and free cash flow, which are relevant for evaluating Cigna's performance. It notes that while fundamentals are supported by strong analyst ratings, insider activity presents a counterbalancing negative signal for investors considering the stock.